Cargando…

Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability

BACKGROUND: Infliximab and other intravenous biologic infusions are increasingly used for chronic disorders like inflammatory bowel disease (IBD). Rapid infliximab and home-based infusions are attractive solutions to address resource and capacity issues for infusion centres, yet infliximab infusion...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bohra, Anuj, Rizvi, Qurat-Al-Ain, Keung, Charlotte Yuen Yu, Vasudevan, Abhinav, van Langenberg, Daniel R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Retrospective Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520608/ https://www.ncbi.nlm.nih.gov/pubmed/33024395 http://dx.doi.org/10.3748/wjg.v26.i36.5437

Ejemplares similares

Challenges and Strategies to Optimising the Quality of Small Bowel Magnetic Resonance Imaging in Crohn’s Disease
por: Bohra, Anuj, et al.
Publicado: (2022)

Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting
por: Berkowitz, Joshua C, et al.
Publicado: (2018)

Replacing Endoscopy with Magnetic Resonance Enterography for Mucosal Activity Assessment in Terminal Ileal Crohn’s Disease: Are We There Yet?
por: Bohra, Anuj, et al.
Publicado: (2023)

Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care
por: Bohra, Anuj, et al.
Publicado: (2020)

A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy
por: Vasudevan, Abhinav, et al.
Publicado: (2019)

Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
por: Cao, Wan-Ting, et al.
Publicado: (2022)

Role of endoscopy in the surveillance and management of colorectal neoplasia in inflammatory bowel disease
por: Manchanda, Shaad, et al.
Publicado: (2019)

The Utility of Faecal Calprotectin, Lactoferrin and Other Faecal Biomarkers in Discriminating Endoscopic Activity in Crohn’s Disease: A Systematic Review and Meta-Analysis
por: Bohra, Anuj, et al.
Publicado: (2023)

Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
por: Gu, Bonita, et al.
Publicado: (2022)

Inflammatory bowel disease and superior mesenteric artery thromboembolism
por: Nicolaides, Steven, et al.
Publicado: (2020)

Increased risk of atrial fibrillation in patients with inflammatory bowel disease: A nationwide population-based study
por: Choi, You-Jung, et al.
Publicado: (2019)

Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?
por: Vasudevan, Abhinav, et al.
Publicado: (2017)

Risk of inflammatory bowel disease in patients with chronic obstructive pulmonary disease: A nationwide, population-based study
por: Lee, Jooyoung, et al.
Publicado: (2019)

Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy
por: Con, Danny, et al.
Publicado: (2022)

The impact of tobacco smoking on treatment choice and efficacy in inflammatory bowel disease
por: Nicolaides, Steven, et al.
Publicado: (2021)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease
por: Ma, Hai-Qin, et al.
Publicado: (2018)

Frequency, types, and treatment of anemia in Turkish patients with inflammatory bowel disease
por: Bengi, Göksel, et al.
Publicado: (2018)

Major depressive disorders in patients with inflammatory bowel disease and rheumatoid arthritis
por: Haider, Maryam Bilal, et al.
Publicado: (2023)

Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases
por: Halling, Morten L, et al.
Publicado: (2017)

Risk factors for postoperative recurrence after primary bowel resection in patients with Crohn’s disease
por: Yang, Kwan Mo, et al.
Publicado: (2017)

Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study
por: Park, Seona, et al.
Publicado: (2018)

Retrospective analysis of complications related to endoscopic retrograde cholangio-pancreatography in patients with cirrhosis vs patients without cirrhosis
por: Bernshteyn, Michelle, et al.
Publicado: (2021)

Valuable clinical indicators for identifying infantile-onset inflammatory bowel disease patients with monogenic diseases
por: Su, Wen, et al.
Publicado: (2021)

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States
por: Smith, Joshua T, et al.
Publicado: (2021)

Infliximab-Associated Acneiform Eruption in a Patient With Inflammatory Bowel Disease
por: Khatana, Usman Feroze, et al.
Publicado: (2021)

Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease
por: Curci, Debora, et al.
Publicado: (2021)

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients
por: Bacsur, Péter, et al.
Publicado: (2021)

Essential role of small bowel capsule endoscopy in reclassification of colonic inflammatory bowel disease type unclassified
por: Monteiro, Sara, et al.
Publicado: (2017)

Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients
por: Lew, Daniel, et al.
Publicado: (2017)

Serological investigation of IgG and IgE antibodies against food antigens in patients with inflammatory bowel disease
por: Wang, Hai-Yang, et al.
Publicado: (2019)

Bowel inflammatory presentations on computed tomography in adult patients with severe aplastic anemia during flared inflammatory episodes
por: Zhao, Xi-Chen, et al.
Publicado: (2023)

Positive correlation between latent Epstein-Barr virus infection and severity of illness in inflammatory bowel disease patients
por: Wei, Hong-Tao, et al.
Publicado: (2023)

Inflammatory bowel disease of the lung: The role of infliximab?()
por: Hayek, Adam J., et al.
Publicado: (2015)

Effect of small bowel transit time on accuracy of video capsule endoscopy in evaluating suspected small bowel bleeding
por: Mohan, Nandakumar, et al.
Publicado: (2022)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
por: Bor, Renáta, et al.
Publicado: (2017)

Uncovering the uncertainty: Risk factors and clinical relevance of P1 lesions on small bowel capsule endoscopy of anemic patients
por: Cúrdia Gonçalves, Tiago, et al.
Publicado: (2016)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mgjm20380nd8bsgpnkrqucpout